Catalyst Pharma jumps after Firdapse update

Catalyst Pharmaceutical (CPRX) is higher by 10% in premarket action.

The company says it has completed a Type B meeting with the FDA regarding the LEMS treatment Firdapse.

CPRX says it updated the regulator on the drug's development program and "confirmed ... the clinical, nonclinical, and chemistry and manufacturing controls requirements that FDA will require to approve an NDA."

The company notes that after discussing "the acceptability of the primary and secondary endpoints specified in the protocol for the ongoing Phase 3 trial, the FDA requested a slight modification in the analyses to be conducted for the endpoints." CPRX does not see this as changing the data being collected and should not alter the number of patients "needed to complete enrollment." (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs